BioLineRx (BLRX) Cost of Revenue (2013 - 2025)

BioLineRx's Cost of Revenue history runs 13 years deep, the most recent figure standing at $40000.0 for Q4 2025.

• In Q4 2025, Cost of Revenue fell 99.34% year-over-year to $40000.0; the TTM figure through Dec 2025 stood at $230000.0 (down 97.52% YoY), while the FY2025 annual figure was $230000.0, down 97.52% from the prior year.
• Cost of Revenue was $40000.0 for Q4 2025 at BioLineRx, down from $84000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $8.1 million in Q3 2023 to a low of -$13.9 million in Q4 2023.
• Historically, Cost of Revenue has averaged $1.0 million across 5 years, with a median of $729500.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 1131.62% in 2022, then tumbled 515.43% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $272000.0 in 2021, then soared by 1131.62% to $3.4 million in 2022, then sank by 515.43% to -$13.9 million in 2023, then jumped by 143.75% to $6.1 million in 2024, then slumped by 99.34% to $40000.0 in 2025.
• The last three Cost of Revenue figures came in at $40000.0 (Q4 2025), $84000.0 (Q3 2025), and $72000.0 (Q2 2025), per Business Quant data.